EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19–9 as a Tool for Prognostic Evaluation in Neoadjuvant‐Treated Pancreatic Ductal Adenocarcinoma

Nora Mattila iD, Riitta Lassila, Harri Mustonen, Caj Haglund, Hanna Seppänen

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71954 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 21.05.2026. Verfasst von Nora Mattila und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Helsinki (UH) and Helsinki University Hospital (HUH), Helsinki, Finland. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, CA-19-9 Antigen, Fibrinogen, Factor VIII. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Finnish Foundation for Cardiovascular Research, Academy of Finland, Blood Disease Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDAC) is highly thrombogenic and lethal, with rising incidence. Combining carbohydrate antigen (CA) 19–9, fibrinogen, coagulation factor VIII (FVIII), albumin, and alkaline phosphatase (ALP) as a diagnostic panel improves diagnostics. We evaluated the prognostic value of this panel in neoadjuvant therapy (NAT) and upfront surgery (US) treated patients undergoing radical‐intent surgery.

Methods

PDAC patients undergoing radical‐intent surgery with available preoperative coagulation variables were included ( n = 205). Patients with borderline resectable tumors received NAT ( n = 76). The diagnostic panel and a modified panel including only fibrinogen, FVIII, and CA 19–9 were assessed preoperatively and evaluated for disease‐specific and disease‐free survival (DSS and DFS, respectively). Follow‐up was for at least two years or until earlier death.

Results

Preoperative fibrinogen was higher in the US‐treated PDAC patients (US PDAC) than in the NAT‐treated PDAC patients (NAT PDAC) ( p < 0.001). Elevated fibrinogen, FVIII, and CA 19–9 predicted poor DSS individually and as a panel among NAT PDAC; a low modified panel score was associated with better DSS than higher panel scores (HR 7.8, 95% CI 1.7–36.1, p = 0.009).

Conclusions

Preoperatively elevated fibrinogen and FVIII indicated a worse prognosis among NAT patients, especially when combined with CA 19–9 in a panel, possibly referring to treatment response after NAT. Further studies should assess whether preoperative dampening of coagulation activity would improve survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalCA-19-9 AntigenFibrinogenFactor VIIIBiomarkers, TumorPancreatic NeoplasmsHumansFemalePrognosisMaleNeoadjuvant TherapyAgedMiddle AgedAdultAged, 80 and over

Stichwörter der Autor:innen

PDACcoagulation activityneoadjuvant therapyprognostic markers

Substanzen

CA-19-9 AntigenFibrinogenFactor VIIIBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgery, University of Helsinki (UH) and Helsinki University Hospital (HUH), Helsinki, Finland.
  • Department of Hematology, Coagulation Disorders Unit, Comprehensive Cancer Center, Research Program in Systems Oncology, UH and HUH, Helsinki, Finland.
  • Translational Cancer Medicine Program, UH and HUH, Helsinki, Finland.
  • ICAN Digital Precision Cancer Medicine Flagship, UH, Helsinki, Finland.

ORCID-Profile: Nora Mattila

Förderung

  • Finnish Foundation for Cardiovascular Research
  • Academy of Finland
  • Blood Disease Research Foundation
  • Finnish governmental subsidy funding
  • Finska Läkaresällskapet
  • Sigrid Juséliuksen Säätiö
  • Suomen Lääketieteen Säätiö
  • Syöpäsäätiö

Zitieren

APA

Mattila, N., Lassila, R., Mustonen, H., Haglund, C., & Seppänen, H. (2026). Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19–9 as a Tool for Prognostic Evaluation in Neoadjuvant‐Treated Pancreatic Ductal Adenocarcinoma. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71954

Vancouver

Mattila N, Lassila R, Mustonen H, Haglund C, Seppänen H. Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19–9 as a Tool for Prognostic Evaluation in Neoadjuvant‐Treated Pancreatic Ductal Adenocarcinoma. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71954

BibTeX
@article{Mattila2026,
  author = {Mattila, Nora and Lassila, Riitta and Mustonen, Harri and Haglund, Caj and Seppänen, Hanna},
  title = {Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19–9 as a Tool for Prognostic Evaluation in Neoadjuvant‐Treated Pancreatic Ductal Adenocarcinoma},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71954}
}
Kostenlos starten →